Skip to content

The Second COVID-19 Wave: Collateral Impact on Patients of Liver Disease

The Second COVID-19 Wave: Collateral Impact on Patients of Liver Disease-A Record Based Cross-Sectional Study.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05167305
Enrollment
1316
Registered
2021-12-22
Start date
2021-12-22
Completion date
2021-12-31
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Diseases

Brief summary

Hospital record of the patients of liver disease admitted from April-May 2021 and April-May 2019 will be reviewed. Patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and the subsequent 30 d and 90 day readmission rate. Monitoring and assessment: Hospital records of all patients of liver disease needing admission during the April-May 2019 and 2021, but without active COVID-19 infection, will be reviewed. Patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and 30 d and 90 d readmission rate.

Interventions

OTHERThis is an observational study

This is an observational study

Sponsors

Institute of Liver and Biliary Sciences, India
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Patients of liver disease requiring hospital admission

Exclusion criteria

1. Active COVID-19 infection at time of admission or acquiring during hospital stay.

Design outcomes

Primary

MeasureTime frame
Comparison of in-hospital mortality rate of patients of liver disease admitted in April-May 2021 and April-May 2019.Until discharge or death

Secondary

MeasureTime frame
Comparison of 30 days readmission rate of patients of liver disease.Day 30
Comparison of 31 to 90 days readmission rate of patients of liver disease.Day 31-90
Comparison of liver transplantation rates in the two time periods i.e., April-May 2021 and April-May 2019.3 months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026